Sarcopenia and impairment in cognitive and physical performance

Magdalena I Tolea, James E Galvin, Magdalena I Tolea, James E Galvin

Abstract

Background: Whether older adults with sarcopenia who underperform controls on tests of physical performance and cognition also have a higher likelihood of combined cognitive-physical impairment is not clear. We assessed the impact of sarcopenia on impairment in both aspects of functionality and the relative contribution of its components, muscle mass and strength.

Methods: Two hundred and twenty-three community-dwelling adults aged 40 years and older (mean age =68.1±10.6 years; 65% female) were recruited and underwent physical functionality, anthropometry, and cognitive testing. Participants with low muscle mass were categorized as pre-sarcopenic; those with low muscle mass and muscle strength as sarcopenic; those with higher muscle mass and low muscle strength only were categorized as non-sarcopenic and were compared on risk of cognitive impairment (Montreal Cognitive Assessment <26; Ascertaining Dementia 8 ≥2), physical impairment (Mini Physical Performance Test <12), both, or neither by ordinal logistic regression.

Results: Compared to controls, those with sarcopenia were six times more likely to have combined cognitive impairment/physical impairment with a fully adjusted model showing a three-fold increased odds ratio. The results were consistent across different measures of global cognition (odds ratio =3.46, 95% confidence interval =1.07-11.45 for the Montreal Cognitive Assessment; odds ratio =3.61, 95% confidence interval =1.11-11.72 for Ascertaining Dementia 8). Pre-sarcopenic participants were not different from controls. The effect of sarcopenia on cognition is related to low muscle strength rather than low muscle mass.

Conclusion: Individuals with sarcopenia are not only more likely to have single but also to have dual impairment in cognitive and physical function. Interventions designed to prevent sarcopenia and improve muscle strength may help reduce the burden of cognitive and physical impairments of functionality in community-dwelling seniors.

Keywords: cognitive impairment; cross-sectional; muscle mass; muscle strength; older adults; physical impairment.

Figures

Figure 1
Figure 1
Distribution of impairment by sarcopenia status. Notes: Controls have lowest level of dual impairment, followed by pre-sarcopenic and finally, sarcopenic participants. Differences are significant at P<0.001.

References

    1. Nagi SZ. The concept and measurement of disability. In: Berkowiz ED, editor. Disability Policies and Government Programs. New York, NY: Praeger; 1979. pp. 1–15.
    1. National Center for Health Statistics . Health, United States, 2012: With Special Feature on Emergency Care. Hyattsville, MD: National Center for Health Statistics; 2012. [Accessed June 20, 2014]. Available from: .
    1. Henry-Sanchez JT, Kurichi JE, Xie D, Pan Q, Stineman MG. Do elderly people at more severe activity of daily living limitation stages fall more? Am J Phys Med Rehabil. 2012;91(7):601–610.
    1. Del Duca GF, Silva SG, Thumé E, Santos IS, Hallal PC. Predictive factors for institutionalization of the elderly: a case-control study. Rev Saude Publica. 2012;46(1):147–153.
    1. Bakula MA, Kovacević D, Sarilar M, Palijan TZ, Kovac M. Quality of life in people with physical disabilities. Coll Antropol. 2011;35(Suppl 2):247–253.
    1. Cesari M, Onder G, Zamboni V, et al. Physical function and self-rated health status as predictors of mortality: results from longitudinal analysis in the ilSIRENTE study. BMC Geriatr. 2008;8:34–42.
    1. Centers for Disease Control and Prevention . Morbidity and Mortality Weekly Report (MMWR), May 10, 2013. Atlanta, GA: Centers for Disease Control and Prevention; [Accessed June 20, 2014]. Self-reported increased confusion or memory loss and associated functional difficulties among adults aged ≥60 Years – 21 States, 2011. Available from: .
    1. Atkinson HH, Cesari M, Kritchevsky SB, et al. Predictors of combined cognitive and physical decline. J Am Geriatr Soc. 2005;53(7):1197–1202.
    1. Hairi NN, Cumming RG, Naganathan V, et al. Loss of muscle strength, mass (sarcopenia), and quality (specific force) and its relationship with functional limitation and physical disability: the Concord Health and Ageing in Men Project. J Am Geriatr Soc. 2010;58(11):2055–2062.
    1. Nourhashémi F, Andrieu S, Gillette-Guyonnet S, et al. Is there a relationship between fat-free soft tissue mass and low cognitive function? Results from a study of 7,105 women. J Am Geriatr Soc. 2002;50(11):1796–1801.
    1. Shin HY, Kim SW, Kim JM, Shin IS, Yoon JS. Association of grip strength with dementia in a Korean older population. Int J Geriatr Psychiatry. 2012;27(5):500–505.
    1. Burns JM, Johnson DK, Watts A, Swerdlow RH, Brooks WM. Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Arch Neurol. 2010;67(4):428–433.
    1. Sternäng O, Reynolds CA, Finkel D, Ernsth-Bravell M, Pedersen NL, Dahl Aslan AK. Factors associated with grip strenght decline in older adults. Age Ageing. 2014 Nov 1; Epub.
    1. MacDonald SW, DeCarlo CA, Dixon RA. Linking biological and cognitive aging: toward improving cgaracterizations of developmental time. J Gerontol B Psychol Sci Soc Sci. 2011;66(Suppl 1):i59–i70.
    1. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699.
    1. Galvin JE, Roe CM, Powlishta KK, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65(4):559–564.
    1. Galvin JE, Roe CM, Coats MA, Morris JC. Patient’s rating of cognitive ability: using the AD8, a brief informant interview, as a self-rating tool to detect dementia. Arch Neurol. 2007;64(5):725–730.
    1. Galvin JE, Fagan AM, Holtzman DM, Mintun MA, Morris JC. Relationship of dementia screening tests with biomarkers of Alzheimer’s disease. Brain. 2010;133(11):3290–3300.
    1. Wilkins Ch, Roe CM, Morris JC. A brief clinical tool to assess physical function: the mini-physical performance test. Arch Gerontol Geriatr. 2010;50(1):96–100.
    1. Reuben DB, Siu AL. An objective measure of physical function of elderly outpatients. The Physical Performance Test. J Am Geriatr Soc. 1990;38(10):1105–1112.
    1. Guralnik JM, Simonsick EM, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85–M94.
    1. Miller DK, Malmstrom TK, Andresen EM, et al. Development and validation of a short portable sarcopenia measure in the African American health project. J Gerontol A Biol Sci Med Sci. 2009;64(3):388–394.
    1. Rantanen T, Era P, Kauppinen M, Heikkinen E. Maximal isometric muscle strength and socioeconomic status, health, and physical activity in 75-year-old persons. J Aging Phys Act. 1994;2:206–220.
    1. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5 Suppl):990S–991S.
    1. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755–763.
    1. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sar-copenia. J Lab Clin Med. 2001;137(4):231–243.
    1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. European Working Group on Sarcopenia in Older People Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–423.
    1. Yoshida D, Suzuki T, Shimada H, et al. Using two different algorithms to determine the prevalence of sarcopenia. Geriatr Gerontol Int. 2014;14(Suppl 1):46–51.
    1. Zigmond AS. The HADS: Hospital Anxiety and Depression Scale. Glasgow: N F E R Nelson Publishing Co; 1994.
    1. Burnham KP, Anderson DR. Model Selection and Multimodel Inference: A Practical Information-Theoreic Approach. 2nd ed. New York, NY: Springer-Verlag Inc; 2002.
    1. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50(5):889–896.
    1. Buchman AS, Wilson RS, Boyle PA, Bienias JL, Bennett DA. Grip strength and the risk of incident Alzheimer’s disease. Neuroepidemiol-ogy. 2007;29(1–2):66–73.
    1. van Kan GA, Cesari M, Gillette-Guyonnet S, Dupuy C, Vellas B, Rolland Y. Association of a 7-year percent change in fat mass and muscle mass with subsequent cognitive dysfunction: the EPIDOS-Toulouse cohort. J Cachexia Sarcopenia Muscle. 2013;4(3):225–229.
    1. Van Kan GA. Epidemiology and consequences of sarcopenia. J Nutr Health Aging. 2009;13(8):708–712.
    1. Clark BC, Manini TM. Functional consequences of sarcopenia and dynapenia in the elderly. Curr Opin Clin Nutr Metab Care. 2010;13(3):271–276.
    1. Studenski SA, Peters KW, Alley DE, et al. The FNIH Sarcopenia Project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547–558.
    1. Bandinelli S, Benvenuti E, Del Lungo I, et al. Measuring muscular strength of the lower limbs by hand-held dynamometer: a standard protocol. Aging (Milano) 1999;11(5):287–293.
    1. Xue QL, Walston JD, Fried LP, Beamer BA. Prediction of risk of falling, physical disability, and frailty by rate of decline in grip strength: the women’s health and aging study. Arch Intern Med. 2011;171(12):1119–1121.
    1. Nilwik R, Snijders T, Leenders M, et al. The decline in skeletal muscle mass with aging is mainly attributed to a reduction in type II muscle fiber size. Exp Gerontol. 2013;48(5):492–498.
    1. Short KR, Bigelow ML, Kahl J, et al. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A. 2005;102(15):5618–5623.
    1. Raji MA, Kuo YF, Snih SA, Markides KS, Peek MK, Ottenbacher KJ. Cognitive status, muscle strength, and subsequent disability in older Mexican Americans. J Am Geriatr Soc. 2005;53(9):1462–1468.
    1. Roubenoff R. Exercise, sarcopenia, cognition, and mood. Nestle Nutr Workshop Ser Clin Perform Programme. 2002;6:151–159. discussion 160–162.
    1. Gonzalez-Freire M, de Cabo R, Studenski SA, Ferrucci L. The neuromuscular junction: aging at the crossroad between nerves and muscle. Front Aging Neurosci. 2014;6
    1. Wilkins CH, Roe CM, Morris JC, Galvin JE. Mild physical impairment predicts future diagnosis of dementia of the Alzheimer’s type. J Am Geriatr Soc. 2013;61(7):1055–1059.
    1. Pratesi A, Tarantini F, Di Bari M. Skeletal muscle: an endocrine organ. Clin Cases Miner Bone Metab. 2013;10(1):11–14.
    1. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006;119(6):526.e9–e17.
    1. Hull M, Strauss S, Berger M, Volk B, Bauer J. Inflammatory mechanisms in Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 1996;246(3):124–128.
    1. Meng SJ, Yu LJ. Oxidative stress, molecular inflammation and sarcopenia. Int J Mol Sci. 2010;11(4):1509–1526.
    1. Semba RD, Ferrucci L, Sun K, et al. Oxidative stress and severe walking disability among older women. Am J Med. 2007;120(12):1084–1089.
    1. Mangialasche F, Polidori MC, Monastero R, et al. Biomarkers of oxidative and nitrosative damage in Alzheimer’s disease and mild cognitive impairment. Ageing Res Rev. 2009;8(4):285–305.
    1. Hsu YH, Liang CK, Chou MY, et al. Association of cognitive impairment, depressive symptoms and sarcopenia among healthy older men in the veterans retirement community in southern Taiwan: a cross-sectional study. Geriatr Gerontol Int. 2014;14(Suppl 1):102–108.
    1. McLean RR, Shardell MD, Alley DE, et al. Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: the foundation for the National Institutes of Health (FNIH) sarcopenia project. J Gerontol A Biol Sci Med Sci. 2014;69(5):576–583.
    1. Liu CK, Leng X, Hsu FC, et al. The impact of sarcopenia on a physical activity intervention: the Lifestyle Interventions and Independence for Elders Pilot Study (LIFE-P) J Nutr Health Aging. 2014;18(1):59–64.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj